Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC – by Rodrigo Sánchez-Bayona. The ERBB2 score identified 36% of patients having poor outcomes with chemo-HP (many of which having HER2 IHC ≤2+). Data with T-DXd/P in these patients highly awaited.”

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab

Authors: Rodrigo Sánchez-Bayona et al.

Paolo Tarantino: Interesting data with HER2DX for predicting the benefit of 1L chemo-HP in HER2+ MBC

More posts featuring Paolo Tarantino on OncoDaily.